Purified active HCV NS2/3 protease

Details Purified active HCV NS2/3 protease Purified active HCV NS2/3 protease

2007-09-04

2007-09-04

Campbell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C435S235100, C435S219000, C530S350000, C424S228100

Reexamination Certificate

active

10650585

ABSTRACT:
A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in the presence of reduced concentration of chaotropic agent or polar additive. The invention further comprises a method for activating this refolded inactive NS2/3 protease by adding an activation detergent. This method produces large amounts of the active NS2/3 protease to allow small molecules and ligands to be screened as potential inhibitors of NS2/3 protease, which may be useful as therapeutic agents against HCV.

REFERENCES:
patent: 5714371 (1998-02-01), Ramanathan
patent: 2004/0054134 (2004-03-01), Steinkuhler et al.
patent: WO 97/08304 (1997-03-01), None
patent: WO97/08304 (1997-03-01), None
patent: WO99/07733 (1999-02-01), None
patent: 0008469 (2000-02-01), None
patent: WO 01/16379 (2001-03-01), None
patent: WO 01/68818 (2001-09-01), None
Yamada et al (Virology 246:104-112, 1998).
Pallaoro et al, Journal of Virology 75:9939-9946, Oct. 2001.
Liliana Chemello et al, The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C; Journal of Hepatolgy1995; vol. 23 (suppl.2) p. 8-12; issue No. 0169-5185; Clinica Medica 2 and Anatonia Patologicu, University of Pudavo, Italy.
M. Wenzel et al; Establishment of a Cell-based Assay for Evaluation of Compounds against HCV NS2-3 Protease Activity; Session 8.H. Paper 91; 1999 p. 409; XP-001041586.
Luisa Pieroni et al; In Vitro Study of the NS2-3 Protease of Hepatitis C Virus; Journal of Virology Sep. 1997 p. 6373-6380 vol. 71 No. 9; American Society for Microbiology.
Paul L. Drake et al; Inhibition of Hepatitis C Virus NS2/3 processing by NS4A peptides; The Journal of Biological Chemistry; 1999, vol. 274 No. 49 p. 34511-34514; The American Society for Biochemistry and Molecular Biology, Inc. USA.
Karen E. Reed et al; Hepatitis C Virus-Encoded NS2-3 Protease: Cleavage-Site Mutagenesis and Requirements for Bimolecular Cleavage; Journal of Virology Jul. 1995 vol. 69 No. 7 p. 4127-4136; American Society for Microbiology.
Elisa Santolini et al; The NS2 Protein of Hepatitis C Virus is a Transmembrane Polypeptide; Journal of Virology Dec. 1995 vol. 69 No. 12 p. 7461-7471; American Society for Microbiology.
Diane Thibeault et al; In Vitro Characterization of a Purified NS2/3 Protease Variant of Hepatitis C Virus; The Journal of Biological Chemistry; Dec. 2001, vol. 276 No. 49 p. 46678-46684; The American Society for Biochemistry and Molecular Biology, Inc.
Copy of International Search Report for PCT/CA 01/01796.
Chirgwin, Przybyla et al.; Isolation of Biologically Active Riboncleic Acid from Sources Enriched in Ribonuclease; Biochemistry; 1979, v. 18; 5294-5299.
Darke, Jacobs et al.; Inhibition of Hepatitis C Virus NS2/3 Procession by NS4A Peptides; J. Biol. Chem.; 1999, V. 274, No. 49; 34511-34514.
Grakoui, McCourt et al.; A second hepatitis C virus-encoded proteinase; Proc. Natl. Acad. Sci. USA; 1993, V. 90; 10583-10587.
Kolykhalvo, Mihalik et al.; Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3' Nontranslated Region are Essential for Virus Replication in Vivo; 2000, V. 74, No. 4; 2046-2051.
Lin, Timasheff; On the role of surface tension in the stabilization of globular proteins; Protein Sci.; 1996, V. 5; 372-381.
Liu, Bhat et al.; The Hepatitis C Virus NS2 Protein Generated by NS2-3 Autocleavage is Required for NS5A Phosphorylation; Biochem. Biophys. Res. Commun.; 1999, V. 254; 572-577.
Neddermann, Clementi et al.; Hyperphosphorylation of the Hepatitis C Virus NS5A Protein Requires an Active NS3 Protease, NS4A, NS4B, and NS5A Encoded on the Same Polyprotein; J. Virol.; 1999, V. 73, No. 12; 9984-9991.
Pallaoro, Lahm et al.; Characterization of the Hepatitis C Virus NS2/3 Processing Reaction by Using a Purified Precursor Protein; J. Virol.; 2001, V. 75, No. 20; 9939-9946.
Pieroni, Santolini et al.; In Vitro Study of the NS2-3 Protease of Hepatitis C Virus; J. Virol.; 1997, V. 71, No. 9; 6373-6380.
Reed, Grakoui et al.; Hepatitis C Virus-Encoded NS2-3 Protease: Cleavage-Site Mutagenesis and Requirements for Bimolecular Cleavage;J. Virol.; 1995, V. 69, No. 7; 4127-4136.
Santolini, Pacini et al.; The NS2 Protein of Hepatitis C Virus is a Transmembrane Polypeptide; J. Virol.; 1995, V. 69, No. 12; 7461-7471.
Thibeault, Maurice et al.; In Vitro Characterization of a Purified NS2/3 Protease Variant of Hepatitis C Virus; J. Biol. Chem.; 2001, V. 276, No. 49; 46678-46684.
Walker, M.A.; Hepatitis C virus: an overview of current approaches and progress; Drug Discovery Today; 1999; V. 4, No. 11; 518-529.
Dymock, Jones et al.; Novel approaches to the treatment of hepatitis C virus infection; Antiviral Chemistry & Chemotherapy; 2000; V. 11(2); 79-96.
Gorbalenya, Snijder; Viral cysteine proteinases; Perspect. Drug Discovery Design; 1996; V. 6; 64-86.
Hijikata, Mizushima et al.; Two Distinct Proteinase Activities Required for the Poscessing of a Putative Nonstructural Precursor Protein of Hepatitis C Virus; J. Virol; 1993; V. 67, No. 8; 4665-4675.
Hirowatari, Hijikata et al.; Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector; Arch. Virol.; 1993; V. 133; 349-356.
Komoda, Hijikata et al.; Processing of hepatitis C viral polyprotein inEscherichia coli; Gene; 1994; V. 145; 221-226.
Wada, Wada et al.; Codon usage tabulated from the GenBank genetic sequence data; Nuc. Acids Research; 1992; V. 20; 2111-2118.
Wong, Albright, et al.; Immobilized Metal Ion Affinity Chromatography (IMAC)—Chemistry and Bioseparation Applications; Separation and Purification Methods; 1991; V. 20(1); 49-106.
Ausubel, Brent et al.; Current Protocols in Molecular Biology; 1994; vol. 1, 2, 3 and 4; Wiley, New York.
Sambrook, Fritsch et al.; Molecular Cloning—A Laboratory Manual, Second Edition; 1989; Cold Spring Harbor Laboratory Press.
Chemello, Cavalletto et al.; The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C; J. Hepatology; 1995; V. 23. Suppl. 2; 8-12.
Wenzel, Troxell et al.; Establishment of a Cell-Based Assay for Evaluation of Compounds against HCV NS2-3 Protease Activity; Prog. & Abstr. Interscience Conf. Antimicrobial Agents & Chemo.; 199; V. 39; 409.
PCT International Search Report of rPCT/CA 01/01796 International Filing Date Dec. 13, 2001.
C. Steinkuehler, et al., In vitro activity of purified HCV NS2/3 protease, 7th International Meeting on Hepatitis C and Related Viruses (molecular Virology and Pathogenesis), Dec. 3-7, 2000, Australia.
M.D. Ryan et al., Hepatitis C virus endopeptidase 2, Family U39, Article No. 567, pp. 1600-1604.
Y. Hirowatari et al., A novel method for analysis of viral proteinase activity encoed by Hepatitis C Virus in Cultured Cells, Analytical Biochemistry 225, p. 113-120 (1995).
Z. Wu et al., Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein, TIBS 23-Mar. 1998, p. 92-94.

Affiliated with

Also associated with

Rating

Purified active HCV NS2/3 protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purified active HCV NS2/3 protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified active HCV NS2/3 protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3800669